Literature DB >> 18523275

IL-7 activates the phosphatidylinositol 3-kinase/AKT pathway in normal human thymocytes but not normal human B cell precursors.

Sonja E Johnson1, Nisha Shah, Anna A Bajer, Tucker W LeBien.   

Abstract

IL-7 signaling culminates in different biological outcomes in distinct lymphoid populations, but knowledge of the biochemical signaling pathways in normal lymphoid populations is incomplete. We analyzed CD127/IL-7Ralpha expression and function in normal (nontransformed) human thymocytes, and human CD19(+) B-lineage cells purified from xenogeneic cord blood stem cell/MS-5 murine stromal cell cultures, to further clarify the role of IL-7 in human B cell development. IL-7 stimulation of CD34(+) immature thymocytes led to phosphorylation (p-) of STAT5, ERK1/2, AKT, and glycogen synthase kinase-3 beta, and increased AKT enzymatic activity. In contrast, IL-7 stimulation of CD34(-) thymocytes (that included CD4(+)/CD8(+) double-positive, and CD4(+) and CD8(+) single-positive cells) only induced p-STAT5. IL-7 stimulation of CD19(+) cells led to robust induction of p-STAT5, but minimal induction of p-ERK1/2 and p-glycogen synthase kinase-3 beta. However, CD19(+) cells expressed endogenous p-ERK1/2, and when rested for several hours following removal from MS-5 underwent de-phosphorylation of ERK1/2. IL-7 stimulation of rested CD19(+) cells resulted in robust induction of p-ERK1/2, but no induction of AKT enzymatic activity. The use of a specific JAK3 antagonist demonstrated that all IL-7 signaling pathways in CD34(+) thymocytes and CD19(+) B-lineage cells were JAK3-dependent. We conclude that human CD34(+) thymocytes and CD19(+) B-lineage cells exhibit similarities in activation of STAT5 and ERK1/2, but differences in activation of the PI3K/AKT pathway. The different induction of PI3K/AKT may at least partially explain the different requirements for IL-7 during human T and B cell development.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18523275     DOI: 10.4049/jimmunol.180.12.8109

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  20 in total

1.  Interleukin-7 is required for CD4(+) T cell activation and autoimmune neuroinflammation.

Authors:  Brian R Lawson; Rosana Gonzalez-Quintial; Theodoros Eleftheriadis; Michael A Farrar; Stephen D Miller; Karsten Sauer; Dorian B McGavern; Dwight H Kono; Roberto Baccala; Argyrios N Theofilopoulos
Journal:  Clin Immunol       Date:  2015-08-25       Impact factor: 3.969

Review 2.  Critical roles of NOTCH1 in acute T-cell lymphoblastic leukemia.

Authors:  Hudan Liu; Mark Y Chiang; Warren S Pear
Journal:  Int J Hematol       Date:  2011-08-05       Impact factor: 2.490

3.  Fox factors fight over T cell quiescence.

Authors:  Cara N Skon; Stephen C Jameson
Journal:  Nat Immunol       Date:  2011-06       Impact factor: 25.606

Review 4.  Transcriptional control of early T and B cell developmental choices.

Authors:  Ellen V Rothenberg
Journal:  Annu Rev Immunol       Date:  2014-01-22       Impact factor: 28.527

5.  IL-7R expression and IL-7 signaling confer a distinct phenotype on developing human B-lineage cells.

Authors:  Sonja E Nodland; Magdalena A Berkowska; Anna A Bajer; Nisha Shah; Dick de Ridder; Jacques J M van Dongen; Tucker W LeBien; Menno C van Zelm
Journal:  Blood       Date:  2011-06-16       Impact factor: 22.113

Review 6.  IL-7 signaling and CD127 receptor regulation in the control of T cell homeostasis.

Authors:  Florent Carrette; Charles D Surh
Journal:  Semin Immunol       Date:  2012-05-01       Impact factor: 11.130

7.  The density of CD10 corresponds to commitment and progression in the human B lymphoid lineage.

Authors:  Michiko Ichii; Kenji Oritani; Takafumi Yokota; Qingzhao Zhang; Karla P Garrett; Yuzuru Kanakura; Paul W Kincade
Journal:  PLoS One       Date:  2010-09-23       Impact factor: 3.240

8.  Interleukin-7 promotes the survival of human CD4+ effector/memory T cells by up-regulating Bcl-2 proteins and activating the JAK/STAT signalling pathway.

Authors:  Nizar Chetoui; Marc Boisvert; Steve Gendron; Fawzi Aoudjit
Journal:  Immunology       Date:  2010-05-04       Impact factor: 7.397

Review 9.  Therapeutic targeting of IL-7Rα signaling pathways in ALL treatment.

Authors:  Sarah D Cramer; Peter D Aplan; Scott K Durum
Journal:  Blood       Date:  2016-06-06       Impact factor: 22.113

10.  Differential IL-7 responses in developing human thymocytes.

Authors:  Julie H Marino; Chibing Tan; Ashlee A Taylor; Caroline Bentley; C Justin Van De Wiele; Richard Ranne; Marco Paliotta; Thomas A Broughan; T Kent Teague
Journal:  Hum Immunol       Date:  2010-01-25       Impact factor: 2.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.